- Home
- LPCN vs CARA Comparison
LPCN vs CARA Comparison
Compare LPCN & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- CARA
- Stock Information
- Founded
- LPCN 1997
- CARA 2004
- Country
- LPCN United States
- CARA United States
- Employees
- LPCN N/A
- CARA N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- CARA Health Care
- Exchange
- LPCN Nasdaq
- CARA Nasdaq
- Market Cap
- LPCN 19.4M
- CARA 23.1M
- IPO Year
- LPCN N/A
- CARA 2014
- Fundamental
- Price
- LPCN $3.38
- CARA $4.97
- Analyst Decision
- LPCN Strong Buy
- CARA Hold
- Analyst Count
- LPCN 1
- CARA 3
- Target Price
- LPCN $10.00
- CARA $12.00
- AVG Volume (30 Days)
- LPCN 33.0K
- CARA 25.1K
- Earning Date
- LPCN 03-06-2025
- CARA 03-03-2025
- Dividend Yield
- LPCN N/A
- CARA N/A
- EPS Growth
- LPCN N/A
- CARA N/A
- EPS
- LPCN N/A
- CARA N/A
- Revenue
- LPCN $7,922,926.00
- CARA $8,686,000.00
- Revenue This Year
- LPCN N/A
- CARA N/A
- Revenue Next Year
- LPCN N/A
- CARA N/A
- P/E Ratio
- LPCN N/A
- CARA N/A
- Revenue Growth
- LPCN N/A
- CARA N/A
- 52 Week Low
- LPCN $3.20
- CARA $2.71
- 52 Week High
- LPCN $11.79
- CARA $13.80
- Technical
- Relative Strength Index (RSI)
- LPCN 30.99
- CARA 49.66
- Support Level
- LPCN $3.42
- CARA $4.94
- Resistance Level
- LPCN $3.62
- CARA $5.73
- Average True Range (ATR)
- LPCN 0.26
- CARA 0.30
- MACD
- LPCN -0.02
- CARA -0.04
- Stochastic Oscillator
- LPCN 1.61
- CARA 30.28
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.